The global Crohn's disease treatment market is slated to reach a valuation of US$ 11.68 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a steady 4.3% CAGR until 2033, being valued at US$ 17.80 billion.
Over the coming years, market growth is predicted to be fueled by the increasing incidence of ulcerative colitis along with Crohn's disease worldwide. Over than 1.6 million Americans experience ulcerative colitis or Crohn's disease, and almost 70,000 new instances of IBD are thought to be identified in the USA each year, as reported by the Crohn's & Colitis Foundation of America. Furthermore, over than 80,000 people in Australia have IBD, based on the RAH Research Fund report.
Growth in the market is anticipated to be fueled by the availability of a robust product pipeline and anticipated releases over the forecast period. For instance, phase II clinical studies are now underway for AbbVie's ABBV-154, an anti-TNF GRM ADC that is anticipated to be on sale in the next years. Comparable to this, Lilly's Mirikizumab is a sizable molecule that may be studied as a therapy for Crohn's disease and is anticipated to be on sale in 2023. Modern treatments concentrate on lowering complication risks, inflammation, and sustained remission. In addition, hospitals and healthcare organizations collaborate closely with pharmaceutical firms to carry out clinical trials and guarantee patient safety. Such initiatives are anticipated to improve research efforts to provide a cutting-edge Crohn's disease therapy.
Also, a crucial development in the market for treating Crohn's disease is the growth of technology. For instance, the market's top players in the treatment of Crohn's disease are placing a strong emphasis on the use of cutting-edge technologies like artificial intelligence (AI) for drug development and the provision of novel therapies for ulcerative colitis and Crohn's disease. Leading firms and tech entrepreneurs are working together to achieve technical advances so they may take use of each other's technology and abilities to develop unique procedures and increase their market positions. For instance, in May 2021, the Israeli tech startup CytoReason announced a deal with Ferring Pharmaceuticals to use AI technology to speed up the drug development process and discover new therapies for Crohn's disease. Developments as such are expected to boost the global revenues in the market for the treatment of Crohn's disease globally from 2023 to 2033.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | US$ 11.2 billion |
| Expected Market Value (2023) | US$ 11.68 billion |
| Projected Forecast Value (2033) | US$ 17.80 billion |
| Global Growth Rate (2023 to 2033) | 4.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global Crohn's disease treatment market grew at a CAGR of 3.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Any area of the small or large intestine may be affected by Crohn's disease. It may involve many segments, or it could be continuous. Some individuals only have the illness in their colon, which is a section of their big intestine. Thus, these symptoms leads on to more of inflammatory bowel diseases and ultimately leads to Crohn’s disease.
Moreover, market expansion is anticipated to be supported by the rise in the use of initiatives including product launches, innovation, expansions, and partnerships. For instance, RINVOQ, a Janus kinase inhibitor, was approved by the USA FDA in March 2022 for the treatment of Crohn's disease. Moreover, AbbVie, Inc. declared the completion of its purchase of Allergan in May 2020, which is anticipated to increase the company's product line for the treatment of Crohn's disease. Moreover, throughout the course of the projected period, market expansion is predicted to be supported by the growing use of innovative products and big molecules. As a result, the global Crohn's Disease Treatment Market is expected to forecast a CAGR of over 4% from 2023 to 2033.
Increasing adoption of biologics have been accelerating the demand
Biological therapy such as anti-interleukin & integrin antibodies and anti-tumor necrosis factor (TNF) are frequently utilised for many inflammatory disorders such as Crohn's disease (CD). For treating individuals who cannot be well managed by steroids or aminosalicylates, they are typically regarded as sufficient.
Nevertheless, some individuals may stop responding to these treatments, especially anti-TNFs. There is a desire for treatments with novel MOAs which are less immunogenic than currently available options, and several new classes of medicines are hoping to hit the market within the next few years. Stelara (ustekinumab) is the last biologic licensed for Crohn's disease.
Due to their improved clinical profiles and practical patient dosage, biologics including anti-integrin as well as interleukin inhibitors are gaining ground in the Crohn's Disease market. Hence, the market for Crohn's disease treatment is anticipated to grow throughout the course of the projected period as a result of these developments.
Rising incidence of Inflammatory Bowel Diseases is driving growth
The market under study has shown significant expansion, which may be attributed to the rising incidence of Crohn's disease and inflammatory bowel illnesses globally. According to projections, there will be 18,30,734 people with Crohn's disease in the 8MM in 2021. Between 2023 and 2033, this number is anticipated to increase to 21,91,544.
As per an article published in 2021 by Journal BMC Gastroenterology, there will be an expected rise of 2.5 fold rise in IBD cases in Iran, and 2.3 fold rise in North America by 2035. Such factors are expected to boost the demand for various therapies and treatments for the diagnosis of Crohn’s disease.
Principal Consultant
Lack of reimbursement policies and high cost are expected to hinder the growth
There is lack of awareness among the various patients suffering from Crohn’s disease in various countries across the globe. Additionally, the higher cost for this kind of treatment, including the drug as well as other cost is expected to restrain the growth of the Crohn’s disease treatment market.
Furthermore, in developing countries like India, Russia and China, there is a scarcity of reimbursement policies for Crohn’s disease treatment, restraining the adoption of the drugs in these regions. The aforementioned issues thus restrict the growth of the Crohn's Disease Treatment Market.
Presence of key players and increasing initiatives are accelerating the growth
During the forecast period, the North American market for Crohn's disease treatment is expected to be the most volatile one. As per Future Market Insights, this region is expected to proliferate at a CAGR of 4.9% from 2023 to 2033.
Due to the existence of several powerful market participants and the numerous strategic efforts they have made in the area, they have achieved this dominance. Regional development is additionally made possible by the rising prescription of innovative treatments, improved payment practises, and high treatment rates in the area. The continued development of innovative treatments and supporting governmental policies are also expected to fuel the region's growth. One of the major organizations that supports numerous clinical and translational studies to identify treatments for colitis and Crohn's disease, for instance, is the Crohn's & Colitis Foundation.
Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 42% in the year 2023.
Enhanced healthcare facilities and strong patient pool to accelerate the growth
During the forecast period, the Asia Pacific market for Crohn's disease treatment is expected to garner a CAGR of 3.6%. Some of the key reasons driving market expansion in the next years include an ageing population, a high chance of acquiring inflammatory illnesses, an increase in the incidence of inflammatory bowel disorders, Crohn's disease, and better healthcare policies in the area.
Also, increased investments by top players in the area and the increasing acceptance of biosimilar and biologics are anticipated to fuel market expansion in the near future. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The immunomodulators segment will gain the dominant market share
Over the course of the forecast period, the immunomodulators segment by drug type is anticipated to occupy a significant share of the global Crohn's Disease Treatment Market. In 2023, this category is anticipated to dominate with a 53% revenue share.
Due to their superior therapeutic activity, the immunomodulators subgroup of medication types now occupies a leading position in the worldwide Crohn's disease therapy market. The key advantage of these medications is that they lessen the long-term requirement for steroids and stop recurrent flares. Because of this, immunomodulators are occasionally referred to as "steroid-sparing" medications. They may also be used with other medications, such as biologics, to assist avoid the development of antibodies, which can reduce the effectiveness of biologics. Such factors are expected to accelerate the growth prospects for Crohn's disease treatment from 2023 to 2033.
The hospital pharmacies segment will demand during the forecast period
According to a report by Future Market Insights, the hospital pharmacy industry would grow within the anticipated time frame. This market sector is expected to hold a 27.3% share of the worldwide market from 2023 to 2033.
Due to the growing number of people visiting hospitals for advice on treatment related to Crohn's disease, the hospital pharmacies sector is anticipated to dominate the worldwide Crohn's disease treatment market. For instance, up to 80% of those suffering from Crohn's required hospitalization at a certain point in 2020, according to an article posted by WebMD LLC, a web publisher of data pertaining to human health and well-being. As a result, these individuals are expected to only buy medications from hospital pharmacies.
The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.
New therapies based on the microbiome and utilizing unique pathways are being developed to treat Crohn's disease. Prominent businesses in the sector are creating unique goods, investing heavily in research and development, and engaging in big acquisitions and partnerships.
Some of the prominent players in the global market for Crohn's disease treatment are:
Some of the important developments of the key players of the market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.3% from 2023 to 2033 |
| Market value in 2023 | US$ 11.68 billion |
| Market value in 2033 | US$ 17.80 billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization & Pricing | Available on Request |
As of 2023, the Crohn's Disease treatment market holds a valuation of US$ 11.68 billion.
The Crohn's Disease treatment market is projected to attain a value of US$ 17.80 billion by 2033, driven by a CAGR of 4.3% between 2023 and 2033.
Novel drug therapies, personalized treatment approaches, and biological interventions are emerging as notable niches in the Crohn's Disease treatment market.
The United States leads the Crohn's Disease treatment market with a strong pharmaceutical sector and established gastroenterology healthcare network.
With a slow-paced CAGR of 3.2%, the Crohn's Disease treatment market's revenues surpassed US$ 11.2 billion in 2022.
1. Executive Summary | Crohn’s Disease (CD) Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Antibiotics 5.3.2. Amino Salicylates 5.3.3. Corticosteroids 5.3.4. Immunomodulators 5.3.5. Other 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Online Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Drug Type 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Type 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. United Kingdom 10.2.1.2. Spain 10.2.1.3. Germany 10.2.1.4. Italy 10.2.1.5. France 10.2.1.6. Rest of Europe 10.2.2. By Drug Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Indonesia 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Drug Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Drug Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Drug Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. South Africa 14.2.1.2. GCC Countries 14.2.1.3. Rest of Middle East and Africa 14.2.2. By Drug Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Drug Type 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Drug Type 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Drug Type 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Drug Type 15.4.2.2. By Distribution Channel 15.5. United Kingdom 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Drug Type 15.5.2.2. By Distribution Channel 15.6. Spain 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Drug Type 15.6.2.2. By Distribution Channel 15.7. Germany 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Drug Type 15.7.2.2. By Distribution Channel 15.8. Italy 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Drug Type 15.8.2.2. By Distribution Channel 15.9. France 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Drug Type 15.9.2.2. By Distribution Channel 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Drug Type 15.10.2.2. By Distribution Channel 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Drug Type 15.11.2.2. By Distribution Channel 15.12. Indonesia 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Drug Type 15.12.2.2. By Distribution Channel 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Drug Type 15.13.2.2. By Distribution Channel 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Drug Type 15.14.2.2. By Distribution Channel 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Drug Type 15.15.2.2. By Distribution Channel 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Drug Type 15.16.2.2. By Distribution Channel 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Drug Type 15.17.2.2. By Distribution Channel 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Drug Type 15.18.2.2. By Distribution Channel 15.19. South Africa 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Drug Type 15.19.2.2. By Distribution Channel 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Drug Type 15.20.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Type 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Abbvie Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Celgene Corporation 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Genetech 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Johnson & Johnson 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Pfizer Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Prometheus Laboratories Inc. (Nestle) 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Salix Pharmaceuticals Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Takeda Pharmaceutical Ltd 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Janssen Pharmaceuticals 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Biogen 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. AstraZeneca 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Crohn’s Disease (CD) Treatment Market
